Here are five things to know.
1. The company reported net income from continuing operations at $5.2 million, compared to a $2.3 million loss over the same period last year. Orthofix acquired Spinal Kinetics during the quarter.
2. The business unit breakdown for net sales is as follows:
• Biostim: $46.2 million, a 3.6 percent increase
• Extremity fixation: $27.5 million, a 14.9 percent increase
• Spine fixation: $20.7 million, a 7.5 percent increase
• Biologics: $14.3 million, a 4.4 percent decrease
Overall, the company reported $108.7 million in net sales.
3. EBITDA was reported at $15.2 million, up from $6.6 million in the first quarter of the previous year. Orthofix’s cash and cash equivalents were $77.1 million at the end of the quarter.
4. For the full year, Orthofix expects to report $458 million to $464 million in net sales.
5. The company completed its acquisition of Spinal Kinetics on April 30, a month after the quarter closed. The transaction includes $45 million in cash plus another $60 million in future contingent milestone payment for FDA approval of the M6-C cervical disc.
More articles on orthopedic devices:
Stryker’s 2018 Q1 sales spike 9.7% to $3.2B: 5 takeaways
Zimmer Biomet makes new partnership: 3 insights
Boost in spine biologics demand drives global spine surgery market: 4 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
